Shilpa Biologicals settles dispute with Sartorius for Rs 9 crore

Litigation LossRegulatory & Legal View source PDF Explain this filing

SHILPAMED · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.2%Reaction day

₹578.50

prior close

₹584.00

announcement price

After-mkt

timing

Nifty Microcap 250market-0.6%-0.6% vs market

Pharmaceuticals peers, median of 163sector-0.6%-0.6% vs sector

On the reaction day the stock moved 0.6 pts less than Nifty Microcap 250 and 0.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.3

10m

-1.9

15m

-2.1

30m

-2.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.2-0.6-0.6-0.6-0.6

Next day

-0.6-0.9+0.3-0.3-0.3

+3.8+0.1+3.7+0.4+3.4

-1.3+0.3-1.6+0.0-1.3

+3.7+1.2+2.6+0.2+3.5

+5.4+0.8+4.5+1.2+4.1

+3.2+0.3+2.9+0.1+3.2

15d

+7.1-0.2+7.3+0.8+6.3

+7.3+0.6+6.8+0.8+6.6

+49.0+4.7+44.3+1.2+47.8

+74.6+5.4+69.2+5.4+69.1

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 163Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Shilpa Medicare's material subsidiary Shilpa Biologicals has settled a commercial dispute with Sartorius Stedim India by paying Rs 9 crore before the Bengaluru Commercial Court. Sartorius had originally claimed about Rs 20.13 crore plus interest. The settlement, executed on 23 June 2026, is limited to this Rs 9 crore payment. No regulatory violation is alleged, and financial impact is confined to the settlement amount.

Likely market impact

Saves ongoing litigation costs; subsidiary pays Rs 9 crore, about 55 percent lower than the original Rs 20.13 crore claim. Limited financial hit on the listed entity.